Jim Ottinger

Jim is a lifelong pharmaceutical industry executive with more than 30 years of strategic regulatory experience, having supported the successful development, approval, and marketing of a number of new drugs throughout his career.

Prior to joining UroGen, Jim served as Senior Vice President of Global Regulatory Affairs at Teva Pharmaceutical Industries, Ltd., where he was responsible for global regulatory oversight of Teva’s portfolio of branded, generic, and over-the-counter products.

Previously, Jim was Vice President of Worldwide Regulatory Affairs of Cephalon, Inc. (acquired by Teva). Earlier in his career, Jim held a variety of senior regulatory positions with Premier Research Group Limited, and regulatory positions of increasing responsibility at Wyeth Research (acquired by Pfizer, Inc.).

Jim holds a bachelor of science in pharmacy from the Temple University School of Pharmacy and is a registered pharmacist in the State of Pennsylvania.